OBJECTIVE: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-α gene single nucleotide polymorphisms (ESR-α SNPs) on the response to therapy. METHODS: A total of 489 postmenopausal women older than 65 years were enrolled into a 3-year double-blind, placebo-controlled clinical trial. RESULTS: In both intent-to-treat and complier (>80% adherent) analysis, there was a significant increase in serum high-density lipoproteins and a significant decrease in serum low-density lipoproteins (LDLs) and the LDL/high-density lipoprotein ratio in all hormone treatment groups compared with placebo (P < 0.05). However, serum triglycerides and very low-density lipoproteins increased in the EPT and ET + calcitriol groups versus placebo (P < 0.05). ESR-α SNPs PvuII and XbaI seemed to have a significant effect on the response to treatment. Genotypes containing the p allele showed a significantly greater decrease in serum cholesterol and very low-density lipoprotein than those having the P allele in the ET + calcitriol group (P < 0.05), and those with the x allele had a significantly greater decrease in serum cholesterol in the hormone therapy + calcitriol group at the end of 3 years versus the X allele, and a greater decrease in serum LDL in alleles x versus the X in the ET + calcitriol group (P < 0.05). CONCLUSIONS:ET with or without progesterone had a favorable effect on lipid profile in postmenopausal older women, and this was dependent on estrogen receptor SNPs--PvuII and XbaI. However, this interaction with ESR-α SNPs needs to be confirmed in larger studies.
RCT Entities:
OBJECTIVE: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-α gene single nucleotide polymorphisms (ESR-α SNPs) on the response to therapy. METHODS: A total of 489 postmenopausal women older than 65 years were enrolled into a 3-year double-blind, placebo-controlled clinical trial. RESULTS: In both intent-to-treat and complier (>80% adherent) analysis, there was a significant increase in serum high-density lipoproteins and a significant decrease in serum low-density lipoproteins (LDLs) and the LDL/high-density lipoprotein ratio in all hormone treatment groups compared with placebo (P < 0.05). However, serum triglycerides and very low-density lipoproteins increased in the EPT and ET + calcitriol groups versus placebo (P < 0.05). ESR-α SNPs PvuII and XbaI seemed to have a significant effect on the response to treatment. Genotypes containing the p allele showed a significantly greater decrease in serum cholesterol and very low-density lipoprotein than those having the P allele in the ET + calcitriol group (P < 0.05), and those with the x allele had a significantly greater decrease in serum cholesterol in the hormone therapy + calcitriol group at the end of 3 years versus the X allele, and a greater decrease in serum LDL in alleles x versus the X in the ET + calcitriol group (P < 0.05). CONCLUSIONS:ET with or without progesterone had a favorable effect on lipid profile in postmenopausal older women, and this was dependent on estrogen receptor SNPs--PvuII and XbaI. However, this interaction with ESR-α SNPs needs to be confirmed in larger studies.
Authors: D M Herrington; D M Reboussin; K B Brosnihan; P C Sharp; S A Shumaker; T E Snyder; C D Furberg; G J Kowalchuk; T D Stuckey; W J Rogers; D H Givens; D Waters Journal: N Engl J Med Date: 2000-08-24 Impact factor: 91.245
Authors: Stefania Lamon-Fava; Bela F Asztalos; Timothy D Howard; David M Reboussin; Katalin V Horvath; Ernst J Schaefer; David M Herrington Journal: Clin Endocrinol (Oxf) Date: 2009-05-29 Impact factor: 3.478
Authors: Nga Thi Thu Tran; Christopher Leigh Blizzard; Khue Ngoc Luong; Ngoc Le Van Ngoc Truong; Bao Quoc Tran; Petr Otahal; Mark R Nelson; Costan G Magnussen; Tan Van Bui; Velandai Srikanth; Thuy Bich Au; Son Thai Ha; Hai Ngoc Phung; Mai Hoang Tran; Michele Callisaya; Seana Gall Journal: PLoS One Date: 2021-08-20 Impact factor: 3.240
Authors: Alanoud Aladel; Alice M Murphy; Jenny Abraham; Neha Shah; Thomas M Barber; Graham Ball; Vinod Menon; Milan K Piya; Philip G McTernan Journal: Nutrients Date: 2022-05-13 Impact factor: 6.706
Authors: Neuza Felix Gomes-Rochette; Letícia Soncini Souza; Bruno Otoni Tommasi; Diego França Pedrosa; Sérgio Ragi Eis; Irani do Carmo Francischetto Fin; Fernando Luiz Herkenhoff Vieira; Jones Bernardes Graceli; Letícia Batista Azevedo Rangel; Ian Victor Silva Journal: PLoS One Date: 2017-02-15 Impact factor: 3.240
Authors: Julia Truthmann; Anja Schienkiewitz; Markus A Busch; Gert B M Mensink; Yong Du; Anja Bosy-Westphal; Hildtraud Knopf; Christa Scheidt-Nave Journal: BMC Public Health Date: 2016-03-08 Impact factor: 3.295